Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
80 Results for "
α-synuclein aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (80)
80 Results for "α-synuclein aggregation" in MCE Product Catalog:
50
50 Publications Verification
Research Areas:
50
50 Publications Verification
Research Areas:
50
50 Publications Verification
Cat. No.: HY-114118A
Purity: 99.92%
Research Areas:
11
11 Cited Publications
Synonyms: 6PPD-Quinone
Category:
Alkaloids Quinones Other Alkaloids Other Diseases Benzene Quinones Endogenous metabolite Disease Research Fields
Target:
6
6 Cited Publications
Cat. No.: HY-N0901A
CAS No.: 17391-18-3
Category:
Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Plants Disease Research Fields Cancer Indole Alkaloids Rubiaceae Extract
Target:
4
Target:
Research Areas:
Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection .
2
Target:
Research Areas:
PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .
2
Target:
Research Areas:
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .
2
2 Cited Publications
Synonyms: ATH434 mesylate
Target:
Research Areas:
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .
1
1 Cited Publications
Synonyms: FD&C Green No. 3; Food green 3; C.I. 42053
1
1
Category:
Umbelliferae Extract Rudbeckia laciniata L. Ketones, Aldehydes, Acids Plants Endogenous metabolite Disease Research Fields Cancer
Target:
1
1 Cited Publications
Cat. No.: HY-W017370
CAS No.: 99-48-9
Synonyms: Anle138b
Target:
Research Areas:
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
Target:
Research Areas:
Dopal is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal exhibits cytotoxicity, induces α-synuclein oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal can be used in research related to Parkinson's disease .
Cat. No.: HY-114118CP
CAS No.: 910463-68-2
Research Areas:
Cat. No.: HY-114118S3
Purity: 96.04%
Cat. No.: HY-160116
CAS No.: 1565797-17-2
Research Areas:
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
Cat. No.: HY-W010041
CAS No.: 488-59-5
Category:
Target:
Cat. No.: HY-N0698
CAS No.: 55750-84-0
Category:
Neurological Disease Terpenoids Diterpenoids Plants Gardenia jasminoides Ellis Disease Research Fields Inflammation/Immunology Rubiaceae Extract
Target:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
